Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GemDOx for Relapsed/Refractory Malignant Lymphoma
NCT00561301Phase 2Unknown
- Sponsor
- Japan Adult Leukemia Study Group
- Start
- Nov 2006
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label trial of gemcitabine and oxaliplatin in non-Hodgkin lymphoma (NHL), sponsored by Japan Adult Leukemia Study Group. Primary endpoint: Objective Response Rate. Status: unknown.
02
Drugs
gemcitabineoxaliplatin
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT00561301.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00561301.